IMVT
Price:
$25.76
Market Cap:
$3.78B
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.[Read more]
Industry
Biotechnology
IPO Date
2019-06-21
Stock Exchange
NASDAQ
Ticker
IMVT
According to Immunovant, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 3.31B. This represents a change of -19.89% compared to the average of 4.13B of the last 4 quarters.
The mean historical Enterprise Value of Immunovant, Inc. over the last ten years is 1.03B. The current 3.31B Enterprise Value has changed 32.04% with respect to the historical average. Over the past ten years (40 quarters), IMVT's Enterprise Value was at its highest in in the December 2023 quarter at 5.40B. The Enterprise Value was at its lowest in in the September 2018 quarter at 0.
Average
1.03B
Median
575.23M
Minimum
99.49M
Maximum
3.73B
Discovering the peaks and valleys of Immunovant, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.26%
Maximum Annual Enterprise Value = 3.73B
Minimum Annual Increase = -88.83%
Minimum Annual Enterprise Value = 99.49M
Year | Enterprise Value | Change |
---|---|---|
2024 | 3.73B | 143.23% |
2023 | 1.53B | 1.26% |
2022 | 112.88M | -88.83% |
2021 | 1.01B | 75.74% |
2020 | 575.23M | 302.24% |
2019 | 143.01M | 43.74% |
The current Enterprise Value of Immunovant, Inc. (IMVT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.79B
5-year avg
1.39B
10-year avg
1.03B
Immunovant, Inc.’s Enterprise Value is greater than Arbutus Biopharma Corporation (574.08M), greater than Arcutis Biotherapeutics, Inc. (1.83B), less than Legend Biotech Corporation (6.11B), greater than Protagonist Therapeutics, Inc. (2.30B), less than IVERIC bio, Inc. (0), less than Akero Therapeutics, Inc. (5.13B), greater than Madrigal Pharmaceuticals, Inc. (1.70B), less than Apellis Pharmaceuticals, Inc. (6.67B), less than 89bio, Inc. (4.20B), greater than Pliant Therapeutics, Inc. (885.64M), greater than Arcellx, Inc. (792.38M), less than Stoke Therapeutics, Inc. (4.06B), greater than Blueprint Medicines Corporation (467.23M), less than Amylyx Pharmaceuticals, Inc. (6.12B), greater than Karuna Therapeutics, Inc. (209.72M), less than Day One Biopharmaceuticals, Inc. (12.43B), greater than null (859.59M),
Company | Enterprise Value | Market cap |
---|---|---|
574.08M | $604.48M | |
1.83B | $1.75B | |
6.11B | $6.22B | |
2.30B | $2.42B | |
0 | $5.51B | |
5.13B | $1.98B | |
1.70B | $6.78B | |
6.67B | $4.13B | |
4.20B | $939.48M | |
885.64M | $811.79M | |
792.38M | $4.15B | |
4.06B | $614.95M | |
467.23M | $5.74B | |
6.12B | $278.99M | |
209.72M | $12.60B | |
12.43B | $1.28B | |
859.59M | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immunovant, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Immunovant, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Immunovant, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Immunovant, Inc. (IMVT)?
What is the 3-year average Enterprise Value for Immunovant, Inc. (IMVT)?
What is the 5-year average Enterprise Value for Immunovant, Inc. (IMVT)?
How does the current Enterprise Value for Immunovant, Inc. (IMVT) compare to its historical average?